{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:16:29Z","timestamp":1760296589546},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2002,1,24]],"date-time":"2002-01-24T00:00:00Z","timestamp":1011830400000},"content-version":"vor","delay-in-days":237,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2001,6]]},"abstract":"<jats:p><jats:bold>Aims\u2002<\/jats:bold> Since relatively little is known about the pharmacokinetics of 6\u2010thioguanine (6TG) in children receiving 6\u2010thioguanine for maintenance therapy of acute lymphoblastic leukaemia (ALL), we studied plasma drug concentrations under standardized conditions and investigated the effect of food on parent drug pharmacokinetics and the accumulation of the active metabolites 6\u2010thioguanine nucleotides (6\u2010TGNs) in red cells.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Methods<\/jats:italic>\n          <\/jats:bold>\n          \u2002Single oral doses of 40\u2003mg of 6\u2010TG were administered both in the fasting and fed state to children with ALL. Pharmacokinetic sampling was performed up to 6\u2003h post dose. Daily oral doses of 40\u2003mg\u2003m<jats:sup>\u22122<\/jats:sup> of 6\u2010TG were administered both fasting and after food over two 4\u2003week periods. Twice weekly samples were taken for metabolite concentrations. The study design was cross\u2010over with each child receiving dosing in either fasted or after food over a 4\u2003week period in each phase.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Results<\/jats:italic>\n          <\/jats:bold>\n          \u2002Eleven patients were studied. A wide interindividual variation in <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> (median 313\u2003pmol\u2003ml<jats:sup>\u22121<\/jats:sup>, range 51\u2013737) and AUC (median 586\u2003pmol\u2003ml<jats:sup>\u22121<\/jats:sup> h, range 156\u20131306) was observed in the fasted state. Concomitant food administration resulted in a significant reduction in <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> (median 71 <jats:italic>vs<\/jats:italic> 313\u2003pmol\u2003ml<jats:sup>\u22121<\/jats:sup>, <jats:italic>P<\/jats:italic>\u2003=\u20030.006, CI from 36 to 426), AUC (median 200 <jats:italic>vs<\/jats:italic> 586\u2003pmol\u2003ml<jats:sup>\u22121<\/jats:sup> h, <jats:italic>P<\/jats:italic>\u2003=\u20030.006, 95% CI from 109 to 692), and time to reach <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> (median 1.5 <jats:italic>vs<\/jats:italic> 3\u2003h, <jats:italic>P<\/jats:italic>\u2003=\u20030.013, 95% CI from 0.74 to 2.73). There was no difference in the steady state concentration of red cell 6\u2010TGNs observed after a 4\u2003week period of 6\u2010TG administered fasting or after food.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Conclusions<\/jats:italic>\n          <\/jats:bold>\n          \u2002Children with ALL demonstrate significant interindividual variation in 6\u2010TG pharmacokinetics. Although there would appear to be a reduction in parent drug <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> and AUC with food there was no difference in 6\u2010TGN concentrations after 4\u2003weeks of 6\u2010TG. Taking the drug on an empty stomach may not be necessary.<\/jats:p>","DOI":"10.1046\/j.0306-5251.2001.01391.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T04:41:52Z","timestamp":1047357712000},"page":"531-539","source":"Crossref","is-referenced-by-count":31,"title":["6\u2010Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6\u2010thioguanine nucleotide concentrations"],"prefix":"10.1111","volume":"51","author":[{"given":"D. L.","family":"Lancaster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Lennard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. S.","family":"Lilleyman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198304283081705"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1986.178"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1987.45"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)80751-6"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00253074"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.3109\/08880018609031233"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF02985158","article-title":"Variability of 6\u2010mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia","volume":"6","author":"Lafolie P","year":"1989","journal-title":"Med Oncol Tumor Pharmacother"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.3109\/08880018909034276"},{"key":"e_1_2_6_10_2","first-page":"417","article-title":"Delayed cytotoxicity of 6\u2010mercaptopurine is compatible with mitotic death caused by DNA damage due to incorporation of 6\u2010thioguanine into DNA as 6\u2010thioguanine nucleotide","volume":"18","author":"Inamochi H","year":"1999","journal-title":"J Exp Clin Cancer Res"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(94)90515-0"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199208000-00002"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(92)80347-S"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.12.1816"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91745-V"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.450"},{"key":"e_1_2_6_17_2","first-page":"1627","article-title":"Pharmacology of 6\u2010thioguanine in man","volume":"31","author":"LePage GA","year":"1971","journal-title":"Cancer Res"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199109068076"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1993.311"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050816"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1983.tb04255.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00253008"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92105-4"},{"key":"e_1_2_6_24_2","first-page":"402","article-title":"Milk could decrease the bioavailability of 6\u2010mercaptopurine","volume":"11","author":"Rivard GE","year":"1989","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-198911000-00001"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199005000-00003"},{"key":"e_1_2_6_27_2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/BF00279977","article-title":"Intraindividual variation in 6\u2010mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia","volume":"40","author":"Lafolie P","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-911x(199710)29:4<252::aid-mpo3>3.0.co;2-l"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)91551-X"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.3109\/07420529309073888"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.0306-5251.2001.01391.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.0306-5251.2001.01391.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.0306-5251.2001.01391.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T06:37:54Z","timestamp":1697524674000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.0306-5251.2001.01391.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["10.1046\/j.0306-5251.2001.01391.x"],"URL":"https:\/\/doi.org\/10.1046\/j.0306-5251.2001.01391.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]}}}